Scarica l'app Stockscreener
7.11
1.28%
0.09
Dopo l'orario di chiusura:
7.11
Fulcrum Therapeutics Inc Borsa (FULC) Ultime notizie
Fulcrum Therapeutics shares climb after Q1 earnings outperform expectations - MSN
Fulcrum Therapeutics (NASDAQ:FULC) Rating Increased to Sell at Wall Street Zen - MarketBeat
Fulcrum Therapeutics (FULC) director receives 64,000 stock options at $8.08 strike price - Stock Titan
Fulcrum Therapeutics (NASDAQ: FULC) director files Form 3 with no shares owned - Stock Titan
Executive pay and auditor vote at Fulcrum Therapeutics (NASDAQ: FULC) - Stock Titan
HC Wainwright Issues Optimistic Estimate for FULC Earnings - MarketBeat
Facioscapulohumeral Muscular Dystrophy Market: Pharma Pipeline Fuels Rapid Expansion – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics - Barchart.com
Facioscapulohumeral Muscular Dystrophy Market: Pharma - openPR.com
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
FULC Should I Buy - Intellectia AI
Fulcrum Therapeutics Shares Surge After Beating Q1 Earnings Estimates - HarianBasis.co
H.C. Wainwright Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Maintains Target Price $25 - Moomoo
A Quick Look at Today's Ratings for Fulcrum Therapeutics(FULC.US), With a Forecast Between $10 to $25 - Moomoo
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q1 2026 Earnings Call Transcript - Insider Monkey
Fulcrum Therapeutics Inc (FULC) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Rising Expenses - GuruFocus
Fulcrum Therapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap DownTime to Sell? - MarketBeat
Fulcrum Therapeutics Q1 Earnings Call Highlights - Yahoo Finance
Fulcrum Therapeutics, Inc. Q1 2026 Financial Results and Forward-Looking Statements Overview - Minichart
Fulcrum Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Fulcrum Therapeutics Reports Positive Pociredir Data in Sickle Cell Disease, Strong Cash Position Through 2029 - Minichart
Value Trap or Opportunity? Fulcrum Therapeutics (FULC) Q1 2026 E - GuruFocus
Fulcrum Therapeutics (FULC) CFO Alan Musso to Retire This Year - GuruFocus
Fulcrum (FULC) Reports Financial Update and Clinical Progress - GuruFocus
Earnings call transcript: Fulcrum Therapeutics reports Q1 2026 earnings beat - Investing.com
Fulcrum Therapeutics Q1 2026 Earnings Call: Complete Transcript - Benzinga
Fulcrum Therapeutics, Inc. Announces Retirement of Alan Musso as Chief Financial Officer - marketscreener.com
Fulcrum Therapeutics (NASDAQ:FULC) Beats Q1 Estimates as Pociredir Data Fuels Optimism - ChartMill
Fulcrum Therapeutics adds former Oxbryta developer to board By Investing.com - Investing.com South Africa
Fulcrum Therapeutics adds former Oxbryta developer to board - Investing.com
Fulcrum Therapeutics Highlights Q1 Results and Sickle Cell Progress - TipRanks
FULCRUM THERAPEUTICS ($FULC) Releases Q1 2026 Earnings - Quiver Quantitative
Fulcrum Therapeutics stock rises nearly 3% on first quarter earnings beat By Investing.com - Investing.com South Africa
Fulcrum Therapeutics stock rises nearly 3% on first quarter earnings beat - Investing.com India
Fulcrum Therapeutics 10-Q: Revenue $0, EPS $(0.25) for Q1 2026 - TradingView
Pociredir data and long cash runway at Fulcrum Therapeutics (NASDAQ: FULC) - Stock Titan
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026 - The Manila Times
Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors - The Manila Times
Fulcrum Therapeutics Inc. (FULC) Tops Q1 EPS by 5c - StreetInsider
[8-K] Fulcrum Therapeutics, Inc. Reports Material Event - Stock Titan
Fulcrum Therapeutics Appoints Dr. Josh Lehrer to Board of Directors - Quiver Quantitative
BRIEF-Fulcrum Therapeutics Q1 Basic EPS USD -0.25 - TradingView
After sickle cell data, Fulcrum plans late-2026 study - Stock Titan
Press Release: Fulcrum Therapeutics Appoints Josh Lehrer to Its Board of Directors - Moomoo
FULC.O Technical Analysis & Stock Price Forecast - Intellectia AI
Fulcrum Therapeutics (FULC) Expected to Announce Quarterly Earnings on Monday - MarketBeat
FULC.O PE Ratio & Valuation, Is FULC.O Overvalued - Intellectia AI
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 4.9%Time to Sell? - MarketBeat
Is Fulcrum Therapeutics (FULC) stock overpriced relative to performance (Pulls Back) 2026-04-20Sector Rotation - Xã Châu Thành
Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET - The Manila Times
Fulcrum schedules April 27 webcast on first-quarter results and updates - Stock Titan
1.77%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):